Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1841 1
1842 2
1846 1
1847 1
1848 1
1852 3
1855 3
1856 4
1859 1
1860 2
1862 2
1863 1
1865 2
1866 1
1869 3
1870 2
1871 1
1873 2
1874 1
1876 2
1877 2
1878 2
1880 1
1881 1
1883 2
1884 1
1887 1
1888 5
1889 1
1890 4
1891 2
1892 1
1894 3
1895 1
1896 3
1897 1
1898 1
1899 3
1901 1
1905 1
1906 4
1907 4
1909 2
1910 1
1911 2
1912 1
1913 3
1915 4
1916 3
1917 7
1918 1
1919 5
1920 6
1921 2
1922 1
1923 1
1924 1
1925 1
1926 1
1927 2
1928 1
1929 3
1930 2
1932 3
1934 2
1935 3
1936 4
1937 1
1938 4
1939 4
1940 1
1941 1
1943 1
1945 5
1946 15
1947 19
1948 20
1949 17
1950 27
1951 26
1952 30
1953 29
1954 34
1955 31
1956 30
1957 25
1958 30
1959 44
1960 24
1961 34
1962 35
1963 39
1964 44
1965 58
1966 65
1967 70
1968 86
1969 63
1970 58
1971 71
1972 74
1973 87
1974 66
1975 277
1976 233
1977 257
1978 288
1979 353
1980 342
1981 364
1982 417
1983 441
1984 486
1985 491
1986 566
1987 612
1988 680
1989 940
1990 862
1991 957
1992 988
1993 1085
1994 1115
1995 1262
1996 1236
1997 1293
1998 1497
1999 1461
2000 1733
2001 1799
2002 1760
2003 2082
2004 2206
2005 2558
2006 2764
2007 2864
2008 3055
2009 3298
2010 3834
2011 4358
2012 4784
2013 5119
2014 5634
2015 5795
2016 6042
2017 6232
2018 6710
2019 7047
2020 8300
2021 9208
2022 9354
2023 8902
2024 4761
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

127,337 results

Results by year

Filters applied: . Clear all
Page 1
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Parker C, et al. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. N Engl J Med. 2013. PMID: 23863050 Free article. Clinical Trial.
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best …
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M. Poeppel TD, et al. Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12. Eur J Nucl Med Mol Imaging. 2018. PMID: 29234845 Free article.
Radium Ra-223 dichloride (radium-223, Xofigo) is a targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. . …
Radium Ra-223 dichloride (radium-223, Xofigo) is a targeted alpha therapy approved for the treatment of castration-r
Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold.
Aprile C, Persico MG, Lodola L, Buroni FE. Aprile C, et al. World J Radiol. 2016 Oct 28;8(10):816-818. doi: 10.4329/wjr.v8.i10.816. World J Radiol. 2016. PMID: 27843540 Free PMC article. Review.
After being approved by the National Drug Agency in several countries, Radium-223 (Ra-223) is gaining wide acceptance in the treatment of bone metastatic castration resistant prostate cancer. ...
After being approved by the National Drug Agency in several countries, Radium-223 (Ra-223) is gaining wide acceptance in the t …
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice.
Roviello G, Catalano M, Ottanelli C, Giorgione R, Rossi V, Gambale E, Casadei C, De Giorgi U, Antonuzzo L. Roviello G, et al. Med Oncol. 2022 Jul 14;39(10):145. doi: 10.1007/s12032-022-01739-3. Med Oncol. 2022. PMID: 35834026 Review.
The treatment landscape for metastatic castration-resistant prostate cancer has evolved extremely in recent years and several drug classes are now available. ...This review describes the presently available and ongoing therapies for patients with CRPC …
The treatment landscape for metastatic castration-resistant prostate cancer has evolved extremely in recent year …
Radium-223 for the treatment of castration-resistant prostate cancer.
El-Amm J, Aragon-Ching JB. El-Amm J, et al. Onco Targets Ther. 2015 May 18;8:1103-9. doi: 10.2147/OTT.S44291. eCollection 2015. Onco Targets Ther. 2015. PMID: 26056474 Free PMC article. Review.
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. ...Radium-223 delivers cytotoxic radiation to the sites of bone metastases and offers the adva …
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone
Radium-223 in metastatic castration resistant prostate cancer.
Vuong W, Sartor O, Pal SK. Vuong W, et al. Asian J Androl. 2014 May-Jun;16(3):348-53. doi: 10.4103/1008-682X.127812. Asian J Androl. 2014. PMID: 24713838 Free PMC article. Review.
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals. ...These agents include sipuleucel-T, cabazitaxel, abiraterone, enzalutamide a …
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Fo …
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.
El-Amm J, Aragon-Ching JB. El-Amm J, et al. Clin Med Insights Oncol. 2016 Mar 23;10(Suppl 1):11-9. doi: 10.4137/CMO.S30751. eCollection 2016. Clin Med Insights Oncol. 2016. PMID: 27042152 Free PMC article. Review.
Radiopharmaceuticals have played a role in targeting the bone microenvironment mainly in pain palliation in mCRPC utilizing strontium or samarium in the remote past, but only radium-223 is the first radiopharmaceutical that has yielded improvement in overall surviva …
Radiopharmaceuticals have played a role in targeting the bone microenvironment mainly in pain palliation in mCRPC utilizing strontium or sam …
Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Iizuka J. Iizuka J. Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:16-23. doi: 10.1111/ajco.13058. Asia Pac J Clin Oncol. 2018. PMID: 30489033 Review.
Radium-223 is a first-in-class targeted alpha therapy indicated for treating bone metastases from metastatic castration-resistant prostate cancer (mCRPC) without visceral metastases. Imaging plays an important role in the se
Radium-223 is a first-in-class targeted alpha therapy indicated for treating bone metastases from metastatic
Radium-223 for Metastatic Castrate-Resistant Prostate Cancer.
Sindhu KK, Nehlsen AD, Stock RG. Sindhu KK, et al. Pract Radiat Oncol. 2022 Jul-Aug;12(4):312-316. doi: 10.1016/j.prro.2022.03.004. Pract Radiat Oncol. 2022. PMID: 35717046 Review.
Administered in the clinic as radium-223 dichloride (Xofigo), radium-223 acts as a calcium mimetic in the human body, forming complexes with hydroxyapatite. In areas of high bone turnover, such as the osteoblastic bone metastases that are …
Administered in the clinic as radium-223 dichloride (Xofigo), radium-223 acts as a calcium mimetic in the human …
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride.
Lien LM, Tvedt B, Heinrich D. Lien LM, et al. Int J Urol Nurs. 2015 Mar;9(1):3-13. doi: 10.1111/ijun.12059. Int J Urol Nurs. 2015. PMID: 26097500 Free PMC article. Review.
Radium-223 dichloride (Ra-223) is the first alpha-particle emitting radiopharmaceutical to be approved for the treatment of patients with castration-resistant prostate cancer and associated bone metastases, and the first bon
Radium-223 dichloride (Ra-223) is the first alpha-particle emitting radiopharmaceutical to be approved for the treatment of pa
127,337 results
You have reached the last available page of results. Please see the User Guide for more information.